GeniVida Blend Limits Bone Loss

WASHINGTONA proprietary blend of soy isoflavone genestein, omega-3 fatty acids DHA and EPA, vitamins D₃ and K₁, and calcium (as geniVida Bone Blend, from DSM Nutritional Products) curtailed bone loss and increased bone mineral density (BMD) in a study presented at the recent 9th International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment in Washington.

Iris Kunz, R&D Human Nutrition and Health, DSM, presented the results of the randomized, placebo-controlled, double blind study, which was performed in conjunction with Creighton University, Omaha, NE.  The six-month trial involved 58 healthy, early postmenopausal women given either geniVida Bone Blend or a calcium-based placebo. After six months, researchers found geniVida had significantly halted bone loss in the femoral neck and Wards Triangle of the hip, compared to bone losses of 1.2 percent and 1.1 percent, respectively, in the calcium placebo group. They further noted a 2.3-percent increase in BMD (Wards Triangle)  in the geniVida group, resulting in a net increase of 3.4 percent. The intervention treatment was determined as safe and well tolerated.

This new study demonstrates that calcium alone is not the answer to optimum bone health, said Joe LaPlaca, senior VP of DSM. It shows that a multi-nutrient approach is needed to solve a multi-factorial health issue. This new evidence complements another new study which showed that geniVida® significantly reduced hot flashes in postmenopausal women by 51 percent over 3 months. Together, these studies provide solutions for unmet short-term and long-term health needs for postmenopausal women.